BioSpace News Archive

Business

Baxter Announces Preliminary Net Sales for the Fourth-Quarter and Full-Year 2019 and Announces Preliminary Full-Year 2020 Guidance

Baxter International Inc. announced preliminary net sales for the quarter and full year ended December 31, 2019, and preliminary full-year 2020 guidance for select financial metrics.

January 12, 2020
·
16 min read
Biotech Bay

Adverum Biotechnologies Reports Continued Momentum with OPTIC Trial for ADVM-022 Intravitreal Gene Therapy in Wet AMD and Provides 2020 Outlook

OPTIC phase 1 trial progressing with plans to complete patient dosing in cohort three, begin enrollment in cohort four in 1Q20

January 12, 2020
·
6 min read
Business

Zymeworks Announces Agreement with Pfizer and Initiation of a New Phase 2 Trial Evaluating ZW25 in Combination with Ibrance® (palbociclib)

Potential for a Novel Chemotherapy-Free Treatment Option for People with Advanced HER2-positive, HR-positive Breast Cancer

January 12, 2020
·
6 min read
Business

Iovance Biotherapeutics and Cellectis Enter into a Research Collaboration and Exclusive Worldwide License Agreement

Iovance Biotherapeutics Will Use TALEN® Technology from Cellectis to Develop Gene-Edited TIL

January 12, 2020
·
9 min read
Genetown

Moderna Builds on Clinical Validation of Systemic Delivery with Two Additional Development Candidates in New Autoimmune Therapeutic Area

mRNA-6231 encodes a long-acting selective IL-2 to preferentially expand regulatory T cells that suppress immune activity in autoimmune diseases

January 12, 2020
·
19 min read
Business

Exelixis Outlines Key Priorities and Anticipated Milestones for 2020-21, Announces Preliminary Fourth Quarter and Full Year 2019 Financial Results, and Provides 2020 Financial Guidance

Company announces anticipated timelines for data readouts from six cabozantinib potentially label-enabling clinical studies and up to three new potential IND candidates

January 12, 2020
·
21 min read
Business

GW Pharmaceuticals Pre-Announces Preliminary Unaudited Fourth Quarter and Full-Year 2019 Net Product Sales

Total Epidiolex® preliminary net product sales of approximately $104 million for the fourth quarter and approximately $296 million for the first full year of sales

January 12, 2020
·
6 min read
Drug Development

Oyster Point Pharma’s OC-01 Nasal Spray Meets Primary Endpoint in Phase 2 Mystic Trial in Subjects With Dry Eye Disease

OC-01 nasal spray showed a statistically significant improvement in Schirmer’s score at Day 84 in both doses tested compared to control

January 12, 2020
·
7 min read
Tyvyt (Sintilimab Injection) Combined with ALIMTA (Pemetrexed) and Platinum Met Predefined Primary Endpoint in Phase 3 ORIENT-11 Study as First-Line Therapy in Nonsquamous NSCLC

Innovent Biologics, Inc. jointly announced with Eli Lilly and Company the results of a Phase 3 study in China; the ORIENT-11 trial of Tyvyt® in combination with ALIMTA® and platinum in first-line advanced or recurrent nonsquamous non-small cell lung cancer, without sensitive EGFR mutation or ALK rearrangement, met the predefined primary endpoint of progression-free survival in an interim analysis.

January 12, 2020
·
8 min read
Genetown

EQRx Launches to Create Innovative Medicines at Dramatically Lower Prices for People, Healthcare Systems and Society

Bolstered with $200M Series A Financing, EQRx Brings Blue-Chip Investors and Life Sciences Leaders Together to Re-Make the Business of Drug Discovery, Development and Delivery to Patients Led by Alexis Borisy as Chairman and CEO and Melanie Nallicheri as President and COO

January 12, 2020
·
4 min read